文献速递白血病造血干细胞移植与细胞治疗

复发AML二次异基因移植:MUD与单倍体供者生存无差异

Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2021-04-10

活动期AML移植OS更差,首次移植至复发间隔较长者OS更好。

要点

  • 二次移植时MUD与单倍体供者的中位OS和2年OS均无显著差异

核心结论

  • 对于复发AML的二次异基因移植,现有数据不足以推荐某一种供者类型优于另一种。
  • 二次移植时处于完全缓解可获得最佳OS。

研究设计与样本

  • 基于EBMT急性白血病工作组(ALWP)注册数据的回顾性比较分析。
  • 纳入2005至2019年间因AML复发接受二次异基因移植的455例成人患者,MUD组320例,单倍体组135例。

主要发现

  • MUD组与单倍体组的2年OS分别为31%与29%。

临床怎么用

  • 选择二次移植供者时,MUD与单倍体均可考虑,无需因供者类型而排除某一选择。
  • 应尽量在完全缓解状态下实施二次异基因移植以改善生存。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Optimal donor choice for a second allogeneic haematopoietic cell transplant (allo-HCT) in relapsed acute myeloid leukaemia (AML) remains unknown. We compared overall survival (OS) using registry data from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) involving 455 adults who received a second allo-HCT from a human leucocyte antigen (HLA)-matched unrelated (MUD) (n = 320) or a haploidentical (n = 135) donor. Eligibility criteria required adults aged ≥18 years who received a second allo-HCT for treating AML relapse between 2005 and 2019. The primary end-point was OS. There was no statistically significant difference in the median (interquartile range) age between the groups, MUD 46 (35-58) versus haploidentical 44 (33-53) years (P = 0·07). The median OS was not different between the MUD and the haploidentical groups (10 vs. 11 months, P = 0·57). Similarly, the 2-year OS was 31% for the MUD and 29% for the haploidentical donor groups. The OS was worse if the procedure was performed with active AML [hazard ratio (HR) 1·42, 95% confidence interval (CI) 1·07-1·89; P = 0·02]. Conversely, a longer time from first allo-HCT to relapse (>13·2 months) was associated with better OS (HR 0·50, 95% CI 0·37-0·69; P < 0·0001). The results of the present analysis limit the ability to recommend one donor type over another when considering a second allo-HCT for relapsed AML. Our findings highlight that best OS is achieved when receiving the second allo-HCT in complete remission.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kharfan-Dabaja MA, Labopin M, Brissot E, et al. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. Br J Haematol. 2021. PMID: 33838047. doi:10.1111/bjh.17426

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。